HK Grey Market | Metis TechBio Soars 191%; Impact Therapeutics Jumps 41%
View all comments(0)
Metis TechBio, one of the "Top Three AI Drug Discovery" companies in Mainland China, soared 191% in Hong Kong’s grey market trading.
Founded in 2020, Metis TechBio focuses on the delivery and application of payloads across a range of biological systems, using artificial intelligence-powered nanotechnology to advance healthcare solutions.

Chinese cancer-drug developer Impact Therapeutics jumped 41% in Hong Kong’s grey market trading.
Founded in 2009, Impact Therapeutics is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Google opens Gemini Omni video to free Vids users after a paid-only start in May

Apple Stock Price Forecast: Where Is the Next Target Price After Record High as iPhone 18 Pro Series Demand Heats Up?

Meta Connect 2026 New Product Roundup: Muse Integrated Into AI Glasses, Can It Drive Meta Revenue Growth?

Micron Earnings Preview: Five Key Things Memory Investors Need to Watch

Meta Stock Forecast: Muse Monetization Path Is Key as JPMorgan Raises Price Target to $920; Can Stock Hit Record High?






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.